The 2nd ADC Analytical Development Summit (April 25-27, 2023 | Boston, MA) is the only meeting focused on optimizing the application of analytical technologies for ADC, from drug-linker and drug substance through to drug product to guide regulatory specifications and submissions, to enhance understanding of your drug and to exert control over your process.
See the complete 2023 event guide here.
You and your team can expect to leave this meeting equipped to have a deeper understanding of your drug and confidently enter conversations with regulators with thought-provoking insights from our expert speaker faculty including:
- Yuan Gao, Head of Analytical Development, ADC Therapeutics
- Jessica Webb, Scientist, Analytical Sciences, AstraZeneca
- Guifeng Jiang, Head of Analytical Development Pharmaceutical Operation, Bolt Biotherapeutics
- Thomas Gardinier, Head of Materials Analysis, Elucida Oncology
- Simon Letarte, Director, Gilead
- Adrienne Wildt, Senior Director of Analytical Development, ImmunoGen
- Shuwen Sun, Principal Scientist, Merck & Co
- Vimal Patel, Vice President, Head of CMC & Supply Chain, Orum Therapeutics
- Julie Beaudet, CMC Staff Scientist, Regeneron Pharmaceuticals
- Sarah Owen, Senior Scientist Potency Assays, Seagen
- Melvin Flores, Director Quality Control Analytical & Microbiology, Sutro Biopharma
- May Zhu, Director of Analytical Development- External Interface Management, Takeda
With 100+ attendees, 4+ hours of dedicated networking, and 3 days of exciting new content, including a pre-conference focus day on comparability studies, this is a conversation you won’t want to miss to hopefully, increase knowledge on your ADC quality attributes to understand and strive for regulatory approval